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Aim. To study an influence of mouse embryonic fibroblasts (C57Fb) transduced with baculovirus vectors 
(BVs), encoding genes for murine Ifn-β or human IL21, on survival and proliferation of the malignant mouse 
melanoma cells (B16) in vitro. Methods. Transduction of cells, construction of BVs, RNA isolation, quantita-
tive PCR. Results. We have shown that the normal C57Fb and B16 tumor cells are sensitive to the anti-prolif-
erative effect of IFNβ. Rapidly proliferating B16 cells were the most sensitive. BV ensured a stable expression 
of Ifnβ mRNA for 5 days in C57Fb/IFNβ cells. The growth of B16 cells was suppressed upon co-cultivation 
with C57Fb/IFNβ or C57Fb/IL21 cells. Conclusions. IFNβ and IL-21 synthesized by the mouse embryonic 
fibroblasts transduced with BVs carrying the Ifnβ or IL-21genes inhibited proliferation of B16 melanoma 
cells in vitro.
K e y w o r d s: mouse embryonic fibroblasts, melanoma cells, interferon β (IFNβ), interleukin-21 (IL-21), 
baculovirus vector, cell transduction.
Introduction
One of the most promising trends in anti-tumor 
therapy is the use of genetically modified cells. 
Over the past several years, genetically engineered 
mesenchymal stem cells (MSCs) have been exten-
sively investigated as a novel vehicle for the cancer 
gene therapy. They are weakly immunogenic and 
exhibit a remarkable migratory property towards tu-
mors. The adult human fibroblasts demonstrate sim-
ilar properties [1–5]. Nowadays a possible applica-
tion of embryonic and fetal fibroblasts, in particular 
mouse embryonic fibroblasts (MEFs), in the regen-
erative cell therapy and in model systems draw 
more and more attention. It has been shown that the 
majority of these cells express antigens of the major 
histocompatibility complex (MHC-I and MHC-II) 
at the low levels. Embryonic and fetal organs con-
tain, along with differentiated cells, stem and acti-
vated (blast) cells, endowed with a high potential of 
proliferation and secreting a unique set of cytokines 
and growth factors in a recipient after grafting [6, 
7]. MEFs actively proliferated in culture until pas-
sage 12; they are widely used as a feeder layer to 
support the growth of embryonic stem cells and also 
they are involved in regulating the organ develop-
ment, wound and burn healing, inflammation and 
fibrosis [8, 9]. Several reports have conclusively 
shown that MEFs are similar to MSCs phenotypi-
cally, genotypically and functionally [10, 11]. Both 
MEFs and MSCs are defined as plastic adherent, 
clonogenic, multipotent fibroblast like the cells that 
have similar morphological appearance, identical 
cell surface markers and the ability to undergo me-
soderm-type cell differentiation into osteocytes, 
adipocytes and chondrocytes [11–13]. Additionally, 
MEFs expressed the markers of embryonic stem 
cells [11]. These unique features make them an at-
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tractive model for the delivery of therapeutic genes 
directly into the tumor microenvironment. 
In the present work we have used interferon β 
(IFNβ) and interleukin-21 (IL-21) as the anti-tumor 
agents. It is known that IFNβ promotes apoptosis, 
exhibits the anti-proliferative effect on tumor cells, 
suppresses the angiogenesis in tumor tissues, reduc-
es an ability of tumor to metastasize, and shows the 
immunomodulatory effects and anti-viral activity 
[14, 15]. However, the clinical application of IFNβ 
had been limited by its severe toxicity associated 
with the excess protein distributing freely through-
out the body upon systemic administration. Due to 
its short drug half-life and insufficient delivery to 
the target tumor cells, a systemic administration of 
IFNβ has shown a limited response to the initial 
therapy for most solid tumors [16]. Transduced stem 
cells can be used as a vehicle to deliver IFNβ or 
other cytokines into the tumor microenvironment 
reducing toxicity and increasing the local concen-
tration of these therapeutic products at the tumor 
sites. Earlier, some model experiments demonstrat-
ed the effectiveness of this approach [16–19]. 
Interleukin-21 (IL-21) is a cytokine with broad 
pleiotropic actions including the regulation of de-
velopment, differentiation and function of lymphoid 
and myeloid cells. The basic mechanism, which is 
associated with the antitumor activity of IL-21, is 
the activation of different subsets of killer cells [20, 
21]. The studies using mouse tumour models in vivo 
as well as clinical trials in patients with advanced 
solid tumours have demonstrated that IL-21 can 
function as a potent antitumour agent [22, 23]. 
Human and murine IL-21 and IL-21 receptors show 
approximately 60 % overall amino acid sequence 
homology with significant conservation in the re-
gions of cytokine–receptor interaction, and to a 
large extent the function of IL-21 has been shown to 
be similar in mouse and human, although several 
discrepancies have also been described [21]. We 
used baculoviral vectors (BVs), derived from an in-
sect virus, for the gene delivery into MEFs. This in-
sect DNA virus has the ability to enter mammalian 
cells without replicating or causing toxicity to the 
transduced cell [24]. Previously we have demon-
strated efficacy of the baculoviruses for such 
task [25]. 
In the present study we investigated the influence 
of MEFs (C57Fb) transduced with recombinant bac-
uloviruses, bearing the mouse Ifnβ or human IL-21 
genes on the survival and proliferation of mouse 
melanoma B16 malignant cells in vitro. 
Materials and Methods
Cell lines
Cells of mouse melanoma B16 were obtained from 
the Bank of Cell Lines of R. E. Kavetsky Institute of 
Experimental pathology, oncology and radiobiology, 
NAS of Ukraine (IEPOR NASU). Mouse embryonic 
fibroblasts were isolated by enzymatic disaggrega-
tion of the soft tissue of 13.5 day old C57BL/6j 
mouse embryos [26]. Primary cells were passaged 
2–3 times. All cells were cultured in DMEM medi-
um (Sigma) supplemented with 10 % fetal bovine 
serum FBS (Sigma), 100 U/ml penicillin and 100 µg/
ml streptomycin at 37 °C in a CO2 incubator. 
Monolayer culture of insect cell line Sf21 was grown 
in TC-100 medium (Sigma) supplemented with 
10 % FBS at 28 °C. 
Baculovirus vectors (BVs)  
and MEF transduction 
BVs were obtained from the Autographa californica 
Multiple NucleoPolyHedrovirus (AcMNPV), using 
the Bac-to-Bac expression system (Invitrogen). The 
following BVs were created: Ac-M-IFN, containing 
the murine Ifnβ gene under regulation of promoter of 
chicken β-actine in the CAG cassette; Ac-IFN-GFP, 
containing two genes: reporter GFP under the CMV 
promoter and the murine Ifnβ gene in the CAG cas-
sette; and also Ac-CMV-IL21 containing the human 
interleukin IL-21 gene under the CMV promoter. As 
controls, the following BVs were used: Ac-M-GFP; 
Ac-M-S18 carrying a gene, encoding the mitochon-
drial ribosomal protein S18-2; and AcFastMam that 
was designed on the base pFastBac plasmid with the 
CAG cassette [27]. The virus was concentrated by 
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centrifugation at 100000 g. The titer of viruses prep-
arations was 2–4×108 pfu/ml. Transduction was per-
formed as desribed previously [28]. C57Fb cells 
were incubated with recombinant BVs at a concen-
tration of 200 moi (multiplicity of infection = pfu per 
cell) for 4 hours at 28 °C in phosphate buffered sa-
line (PBS), followed by addition of 1.5 ml DMEM 
medium and culturing for 16 hours at 37 °C. At the 
end of the incubation period, the virus solution was 
discarded, cells were washed with PBS and 2 ml 
DMEM medium containing 10 % FBS was added.
Analysis of cell proliferation
B16 melanoma cells were seeded on 6-well plates at a 
concentration of 2×105 cells/well and cultured toge-
ther with C57Fb cells transduced with BVs carrying 
the murine Ifnβ or human IL-21 gene at a concentra-
tion of 2×104 cells/well. In the control experiments, 
cells were seeded in the same amounts and ratios 
(1:10). As a control, we used the following variants of 
co-culturing cells: C57Fb: B16; C57Fb/GFP: B16; 
C57Fb/S18: B16; C57Fb/FastMam: B16. Also cells 
C57Fb and B16 were transduced with the above BVs 
cultured alone (2×105 cells/well). And “pure” con-
trol – cells B16 and C57Fb cultured alone (not trans-
duced) at a concentration of 2×105 cells/well. 
In all experiments, the cells were cultured for 
5 days at the standard conditions without replace-
ment of the culture medium. Cells were removed 
from the culture plates by the trypsin EDTA solution 
and re-suspended in PBS supplemented with serum 
(10 % FBS). The total cell number was then calcu-
lated. All experiments were performed in triplicate. 
The results are presented as the relative number of 
cells (in % of the cell number in controls, see [16] 
for description). 
Assessment of the Ifnβ gene expression
To monitor the kinetics of  Ifnβ gene expression in 
transduced MEFs, the samples were collected at 0, 
24, 48, 72, 96, and 120 hours after transduction. As 
the controls the C57Fb intact cells and C57Fb cells 
transduced with AcFastMam at 0 and 24 hours were 
used.
RNA isolation and cDNA synthesis
RNA was isolated, using the RNA isolation kit 
(Fermentas/Thermo Fisher Scientific), according to 
the manufacturer’s protocol. RNA concentration 
was measured, using a Nanodrop spectrophotometer 
(Thermo Fisher Scientific). The RNA was treated 
with DNase (Fermentas/ Thermo Fisher Scientific), 
and 1 µg of RNA was applied in cDNA synthesis, 
using oligo-dT primer and cDNA synthesis kit 
(Fermentas). 2 µl of the synthesized cDNA was used 
for q-PCR.
Real-Time q-PCR
The relative expression level of the gene  Ifnβ was 
assessed by q-PCR, using SYBR Green (Maxima 
SYBR qPCR Master Mix/Thermo Fisher Scientific) 
on a Real-Time thermocycler (CFX96 Real-time 
System C1000 Thermal Cycler / BIO-RAD). The 
TBP was used as the reference gene. The following 
primers were used: TbpF1 5’-CCCCACAACTCTT 
CCATTCT-3’; TbpR1 5’-GCAGGAGTGATAGGG 
GTGAT-3’; Ifn-bF 5’-CCCTATGGAGATGACGG 
AGA-3’; Ifn-bR5’-CAGTCTGGAGAAATTGT-3’. 
Amplification parameters were: 50 °C – 20 min, 
95 °C – 10 min, (94 °C – 25 s, 60 °C – 25 s, 72 °C – 
25 s) for 40 cycles, and 72 °C – 2 min.
Statistical analysis
Statistical analysis was performed using the Student’s 
t-test.
Results and Discussion
Effect of MEF (C57Fb) and tumor B16 cells 
transduced with BVs, on the proliferation 
of melanoma cells B16 in vitro 
To examine a possible anti-proliferative effect of the 
C57Fb cells transduced with the BVs carrying the 
Ifnβ  or IL-21 genes, these cells were co-cultured 
with the malignant B16 cells in vitro. We have found 
that proliferation of the B16 cells was inhibited by 
the C57Fb transduced BVs with gene Ifnβ (Fig. 1, 
columns 6, 7) in comparison with the controls (co-
lumns 1–5). The amount of B16 melanoma cells in 
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the control on 5th day of culturing – 6x106 cells/well 
was taken for 100 %. The relative number of the B16 
cells co-cultured with C57Fb/IFNβ or C57Fb/IFNβ-
GFP cells (4.5±2.7 % and 2.8±1.2 %, respectively) 
was decreased significantly in comparison with all 
the controls, and these differences were statistically 
significant (p < 0.001). The number of B16 cells cul-
tured together with C57Fb/FastMam cells (Fig. 1, 
column 5) was significantly lower compared to the 
number of B16 cell cultured alone (p < 0.01). 
Moreover, the significant reduction in the number of 
these cells was observed (p < 0.05) when compared 
with the control mixtures of cells (Fig. 1, co lumns 
2–4). It was shown earlier that baculovirus transduc-
tion could activate the TLR3 (toll-like receptor) 
pathway in MSCs and triggered secretion of various 
cytokines, including IFNα and IFNβ, although a le-
vel of their secretion was low [29, 30]. Nevertheless, 
the properties of MEFs and their production of en-
dogenous IFN in response to transduction of BVs 
were not investigated earlier. We also found that in 
all control mixtures of B16 cells with C57Fb the 
number of B16 cells was statistically significantly 
reduced (p < 0.05) compared with the growth of B16 
cells alone. Therefore, modeling in vitro interaction 
of heterologous cells in tumor – melanoma cells 
(B16) and fibroblasts (MEFs), we have shown that 
IFNβ, synthesized by C57Fb/IFNβ or C57Fb/IFNβ-
GFP cells, inhibits the proliferation of tumor B16 
cells. The presented results are consistent with the 
earlier reports [16, 31, 32]. Notably, in the referred 
here studies MSCs used showed a stimulating effect 
on the tumor cells (including melanoma cells) 
growth when co-cultured in vitro. Recently, there are 
increasing evidences that MSCs exhibit the promo-
tion or inhibition of the tumor growth and the inva-
sion through direct or indirect interaction with the 
tumor cells [33]. As discussed above, the C57Fb 
cells exerted an inhibitory effect on the B16 tumor 
cell growth. This fact also indicates the perspective 
of using MEFs as a vector in the experimental mouse 
models of melanoma in vivo.
When B16 cells were co-cultured with C57Fb/
IL21 cells (Fig. 1, column 8) a significant decrease 
in the number of B16 cells was observed, compared 
with a “pure” control (p < 0.01) and the control mix-
tures of cells (p < 0.05). Although IL-21 was origi-
nally described as an important regulator of T, B and 
NK cells, which play key roles in antitumoral im-
munity, our results have shown that IL21 inhibits 
proliferation of malignant melanoma cells upon co-
cultivating with C57Fb/IL21 cells in vitro. Further 
studies are needed to clarify, whether the melanoma 
cells are a direct target of IL-21 or this cytokine acts 
indirectly by activating intracellular processes in fi-
broblasts. 
Since the tumor cells interact with each other and 
with the surrounding normal cells, we considered in-
teresting to model the interaction between homolo-
gous cells in tumor, using B16 cells and B16, trans-
duced with BVs carrying the Ifnβ or IL-21 genes. A 
significant decrease in the number of tumor cells 
(Fig. 2, columns 5–6) occurred when B16 cells were 
co-cultured with B16, transduced with BV contain-
ing the Ifnβ gene, in comparison with the controls 
(columns 1–4): 21.7 % (B16/IFNβ:B16) and 30.3 % 
(B16/IFNβ-GFP:B16). The observed difference was 
statistically significant (p < 0.001).
Fig. 1. Effect of co-culturing of embryonic fibroblasts C57Fb 
expressing IFNβ or IL-21, on the proliferation of B16 cells in 
vitro. 1 – “pure” control B16 cells; control mixtures of cells: 2 – 
C57Fb: B16; 3 – C57Fb/GFP: B16; 4 – C57Fb/S18: B16; 5 – 
C57Fb/FastMam: B16; cell mixtures in experiment: 6 - C57Fb/
IFNβ: B16; 7 – C57Fb/IFNβ-GFP: B16; 8 – C57Fb/IL21: B16. 
The differences are significant at *p < 0,05; **p <0,01; ***p < 
0,001 compared to the control.
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Thus, when co-cultured the homologous cells 
(B16/IFNβ:B16, B16/IFNβ-GFP:B16) or the heter-
ologous (C57Fb/IFNβ:B16, C57Fb/IFNβ-GFP:B16) 
cells as well, IFNβ synthesized by B16 or C57Fb 
cells inhibits the proliferation of tumor B16 cells 
(Fig. 3). However, the observed effect is more pro-
nounced when the heterologous cells were co-cul-
tured. Thus, at the 5th day of co-cultivation of B16 
cells with C57Fb/IFNβ or C57Fb/IFNβ-GFP the 
number of B16 cells decreased 5 and 11 fold, in 
comparison with co-culturing the homologous 
cells – B16/IFNβ:B16 and B16/IFNβ-GFP:B16. 
The number of B16 cells cultured together with 
B16/FastMam cells was lower, compared to the 
number of B16 cells in a “pure” control and the con-
trol mixtures (Fig. 2, columns 2, 3) with statistically 
significant differences (p<0.01). 
Notably, the control cell mixtures containing 
MEFs (Fig. 1) showed a higher inhibiting capacity 
compared with the similar mixtures that contained 
the homologous B16 cells (Fig. 2), and compared 
with the transduced cell B16 cultured alone (Fig. 4). 
Similar results on suppression of the tumor cell pro-
liferation by fibroblasts were also reported earlier 
[34–36]. It was shown that mouse and human fibro-
blasts can inhibit the proliferation of tumor cells, 
when co-cultured in vitro. Yet, their inhibitory abili-
ty varies, depending on the origin of the tumor cells 
and fibroblasts. The effective inhibition was ob-
served when fibroblasts formed a monolayer, and 
inhibition was due to direct cell-to-cell contacts. 
Tumor cells interact with other cells and extracellu-
lar matrix through a wide range of adhesion mole-
cules localized on the surface of tumor cells and fi-
broblasts. It was also noted that soluble factors (dif-
ferent proteins, including cytokines) secreted by fi-
broblasts contribute to the inhibition of proliferation 
and motility of tumor cells. In our study, despite the 
fact that the ratio of MEFs and tumor cells was 1:10, 
the growth of B16 tumor cells was inhibited signifi-
cantly on the fifth day of co-cultivation. When B16 
cells were co-cultured with B16, transduced with 
Fig. 2. Effect of co-culture of melanoma B16 cells transduced 
with BVs and non transduced B16 cells in vitro. 1. – B16 control 
cells; 2. – B16/GFP: B16; 3. – B16/S18: B16; 4. – B16/Fast-
Mam: B16; 5. – B16/IFNβ: B16; 6. – B16/IFNβ-GFP: B16; 7. 
– B16/IL21: B16. The differences are significant at **p<0.01; 
***p< 0.001 compared to the control.
   
B16 B16:C57Fb/IFNβ-GFP B16/IFNβ-GFP B16:B16/IFNβ-GFP
Fig. 3. Antiproliferative influence of IFNβ, synthesized by C57Fb or by tumor B16 cells, transduced with BVs, on melanoma cells 
(magnification × 10).
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BV carrying IL-21 no difference in the growth of tu-
mor cells was observed (Fig. 2, column 7). 
Analysis of proliferation of B16 and C57Fb cells 
(cultured alone), transduced with BV carrying Ifnβ, 
revealed inhibition of the cell growth on the fifth day 
in comparison with all the control variants (Fig. 4, 
5): 19.0 % B16/IFNβ and 22.4 % B16/IFNβ-GFP; 
49.8% C57Fb/IFNβ and 33.3 % C57Fb/IFNβ-GFP. 
The number of C57Fb cells in a “pure” control on 
the fifth day of culturing – 8.6x105 cells/well was 
taken for 100 %.The observed difference was statis-
tically significant (p < 0.001). 
The growth of B16/FastMam cells was also sig-
nificantly inhibited (p < 0.05) in comparison with the 
growth of B16 cells in control (Fig. 4, column 4). 
The number of B16/IL21 cells does not differ from 
this index in the control variants. We also observed a 
significant reduction in the number of C57Fb/GFP, 
C57Fb/S18 and C57Fb/FastMam cells in compari-
son with a “pure” control (p < 0.05, p < 0.01) (Fig. 5). 
Thus, C57Fb cells showed increased responsiveness 
to the transduction with BVs as compared with B16 
cells. As previously reported, this effect is probably 
associated with the induction of endogenous inter-
feron or other cytokines in response to the baculovi-
rus transduction of these cells and also depends on 
the expression of introduced transgenes. The number 
of C57Fb/IL21 cells was statistically significantly 
reduced (p < 0.05) compared with the growth of 
C57Fb cells alone. This is in line with previous fin-
dings, showing that IL-21 inhibits proliferation of 
C57Fb as B16 cells which were co-cultured with 
C57Fb/IL21 (Fig. 1).
Noteworthy, C57Fb cells were more resistant to 
the anti-proliferative effect of IFNβ produced by 
these cells. It is known that the secreted IFNβ binds 
to specific receptors on the membrane and functions 
as a regulator of the cell proliferation through auto-
crine (affects the secreting cell itself), and paracrine 
(acts on neighboring cells and tissue) pathways [37]. 
Thus, IFNβ produced by the transduced C57Fb/
IFNβ, C57Fb/IFNβ-GFP, B16/IFNβ, B16/IFNβ-
GFP cells inhibited their proliferation, and when co-
cultured with B16 cells it suppressed the melanoma 
cells proliferation. 
Analysis of Ifnβ expression in C57Fb cells, 
transduced with BV carrying Ac-M-IFNβ
To assess the kinetics of Ifnβ expression in C57Fb 
cells, transduced with BV, q-PCR analysis was per-
Fig. 4. The results of cell culture of melanoma B16, transduced 
with various BVs: 1 – control cells B16; 2 – B16/GFP; 3 – 
B16/S18; 4 – B16/FastMam; 5 – B16/IFNβ; 6 – B16/IFNβ-
GFP; 7 – B16/IL21 The differences are significant at *p < 0.05; 
***p < 0.001 compared to the control.
Fig. 5. The results of culturing mouse embryonic fibroblasts 
C57Fb transduced with various BVs: 1 – control cells C57Fb; 
2 – C57Fb/GFP; 3 – C57Fb/S18; 4 – C57Fb/FastMam; 5 –
C57Fb/IFNβ; 6 – C57Fb/IFNβ-GFP; 7 – C57Fb/IL21. The dif-
ferences are significant at *p < 0.05; **p < 0.01; ***p < 0.001 
compared to the control.
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formed. It is known that BVs provide transient ex-
pression of transgenes in non-permissive mammali-
an cells in the absence of viral replication and a 
gradual loss of viral DNA upon cell division. As was 
shown earlier, the expression of GFP reporter pro-
tein may last for 30 days gradually decreasing, but 
stored in some single cells [28, 30]. Using q-PCR, 
we showed that Ifnβ was expressed at a high level 
for 120 hours, substantially equal to that observed 
immediately after transduction (Fig. 6). Maximum 
value in our system was observed on the twenty-
fourth hour post transduction. The transduction of 
C57Fb cells with the control baculovirus (Ac-
FastMam) led to a minor increase in the synthesis of 
endogenous IFNβ that within 24 hours falls to a low-
er level than in cells without transduction (Fig. 6). 
These data are consistent with the previously repor-
ted and are associated with a response to introduc-
tion of BV by secreting cytokines including inter-
feron [30]. Consequently, when B16 cells were co-
cultured with C57Fb/IFNβ cells, IFNβ produced by 
MEF, provides a permanent inhibitory effect on the 
tumor cells for 120 hours. 
Conclusions
We showed that IFNβ, synthesized by C57Fb MEFs 
or by tumor B16 cells transduced with BVs, carrying 
the Ifnβ gene, inhibited the proliferation of malig-
nant mouse B16 melanoma cells in vitro. The effec-
tiveness of inhibition of the B16 cells proliferation 
was higher when the heterologous cells were co-cul-
tured. Hence, the interactions between MEFs and 
tumor cells contribute mostly to the inhibition of tu-
mor cell proliferation.
We found that Ifnβ was stably expressed in C57Fb 
cells transduced with BV Ac-M-IFNβ for 120 hours. 
Noteworthy, C57Fb/IFNβ cells were more resistant to 
the anti-proliferative effect of IFNβ, than B16/IFNβ 
cells. The growth of B16 cells was inhibited upon co-
cultivating with C57Fb cells transduced with BV car-
rying the IL-21 gene. Overall, we have demonstrated 
that MEFs can be used as potential anti-tumor vehi-
cles delivering IFNβ or IL-21 to malignant melano-
ma. The preliminary findings of the present study sup-
port the further investigation of MEF-based gene 
therapy as a strategy for the treatment of melanoma 
B16 or other malignant tumors in vivo.
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Ембріональні фібробласти миші, які експресують IFNβ або 
IL-21, інгібують проліферацію клітин меланоми in vitro
І. М. Вагіна, О. А. Захарук, Л. І. Строковська,  
Ю. В. Вагін, В. І. Кашуба
Мета. Вивчення впливу ембріональних фібробластів миші 
(C57Fb), трансдукованих бакуловірусними векторами (БВ), що 
містять гени мишачого Ifnβ або IL-21 людини, на виживаність і 
проліферацію злоякісних клітин меланоми миші (B16) in vitro. 
Методи. Трансдукція клітин, конструювання БВ, виділення 
РНК, кількісна ПЛР. Результати. Показано, що до антипролі-
феративного ефекту IFNβ виявилися чутливими всі досліджу-
вані клітини як нормальні C57Fb, так і пухлинні B16; макси-
мальну чутливість мали клітини B16, які швидко діляться. БВ 
забезпечували стабільну експресію гена Ifnβ на рівні мРНК 
протягом 5 діб в клітинах C57Fb/IFNβ. Проліферація клітин 
B16 пригнічувалася при сумісному культивуванні з C57Fb/
IFNβ або C57Fb/IL21 клітинами. Висновки. IFNβ і IL-21, син-
тезовані ембріональними фібробластами С57Fb, трансдукова-
ними БВ з генами Ifnβ або IL-21 інгібували проліферацію клі-
тин В16 при їх сумісному культивуванні in vitro.
К л юч ов і  с л ов а: ембріональні фібробласти, клітини мела-
номи, інтерферон β (IFNβ), інтерлейкін-21 (IL-21), бакулові-
русні вектори, трансдукція.
Эмбриональные фибробласты мыши, экспрессирующие 
IFNβ или IL-21, ингибируют пролиферацию клеток 
меланомы in vitro
И. Н. Вагина, Е. А. Захарук, Л. И. Строковская, 
Ю. В. Вагин, В. И. Кашуба
Цель. Изучение влияния эмбриональных фибробластов 
мыши (C57Fb), трансдуцированных бакуловирусными векто-
рами (БВ), содержащими гены мышиного Ifnβ или IL-21 че-
ловека, на выживаемость и пролиферацию злокачественных 
клеток меланомы мыши (В16) in vitro. Методы. Трансдукция 
клеток, конструирование БВ, выделение РНК, количествен-
ная ПЦР. Результаты. Показано, что к антипролиферативно-
му эффекту IFNβ оказались чувствительными все исследуе-
мые клетки как нормальные C57Fb, так и опухолевые B16; 
максимальной чувствительностью обладали быстро делящи-
еся клетки B16. БВ обеспечивали стабильную экспрессию 
гена Ifnβ на уровне мРНК в течение 5 суток в клетках C57Fb/
IFNβ. Пролиферация клеток B16 подавлялась при со-культи-
вировании с C57Fb/IFNβ или C57Fb/IL21 клетками. Выводы. 
IFNβ и IL-21, синтезируемые мышиными эмбриональными 
фибробластами, транс ду цированными БВ с генами Ifnβ или 
IL-21 ингибировали пролиферацию клеток меланомы В16 
in vitro. 
К л юч е в ы е  с л ов а: эмбриональные фибробласты, клетки 
меланомы, интерферон β (IFNβ), интерлейкин-21 (IL-21), баку-
ловирусные векторы, трансдукция. 
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